Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akbar Dorgalaleh has a total of 317 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prenatal Diagnosis of Severe Factor VII Deficiency in the Setting of Maternal Breast Cancer

    by Mahmood Shams, Nader Safarian, Samila Farokhimanesh, Akbar Dorgalaleh

    Congenital factor VII (FVII) deficiency is the most common rare bleeding disorder (RBD), presenting with various clinical manifestations. Given the heightened risk of life-threatening bleeding and fatal hemorrhagic complications, prompt detection of the disorder is critical, especially in cases with low FVII levels and a history of familial severe clinical presentations. In such cases, prenatal diagnosis (PND) emerges as a life-saving option. In this study, we reported two PNDs in a family with a positive family history of severe FVII deficiency (G (p.Met1Val) variant in exon 1 of the affected girl, who was homozygous for this variant in the F7 gene and had severe FVII deficiency (G variant, leading to termination of the second pregnancy. During the third pregnancy (Second PND), while the mother was being cared for for breast cancer, the homozygous child was born without complications, and the mother underwent mastectomy following delivery. Over the following two years, the child has remained asymptomatic, and the mother has also remained healthy after the mastectomy. Successful PND of severe FVII deficiency was achieved through c.1A>G variant detection, with coordinated multidisciplinary care enabling favorable maternal and fetal outcomes despite concurrent breast cancer treatment.

  • Open Access

    Factor VII Padua: a systematic review of reported cases, diagnosis, clinical manifestations, and management strategies

    by Seyed Mehrab Safdari, Mahmood Shams, Samin Alavi, Akbar Dorgalaleh

    Factor VII (FVII) Padua is a rare inherited disorder caused by a missense variant in the F7 gene (Arg364Gln), resulting in variable FVII activity depending on the thromboplastin source used in assays. Although often linked to a hypercoagulable state, critical gaps remain in understanding its diagnosis, clinical manifestations, and geographic distribution. Following PRISMA guidelines, a systematic search of PubMed, Scopus, and Web of Science was conducted through February 2026 to identify studies reporting FVII Padua. Data on demographics, laboratory findings, and bleeding or thrombotic events were extracted from eligible publications. Thirty-six studies comprising 75 patients were identified. Most cases originated from Italy (22.6%), Iran (20%), the USA (17.3%), France (12%), and Brazil (9.3%). Ages ranged from 5 to 79 years. Sex information was available for 50 patients, of whom 27 (54%) were female and 23 (46%) were male. Prolonged prothrombin time and markedly reduced FVII activity using rabbit-brain thromboplastins were key diagnostic features, while human or recombinant thromboplastins showed milder reductions. Nearly half of the patients (n = 28; 49%) were asymptomatic; however, some experienced severe bleeding, including postpartum hemorrhage (n = 1; 1.7%) and gastrointestinal bleeding (GIB) (n = 3; ~5%). Thrombotic events were reported in six patients out of 13 (46%), including deep vein thrombosis (DVT) in two patients (33.3%) and pulmonary embolism (PE) in one patient (16.6%). This study demonstrates the global distribution and clinical heterogeneity of FVII Padua, emphasizing the need for thromboplastin-specific diagnostic evaluation and individualized management. Further research is essential to address existing diagnostic and therapeutic gaps.

  • Factor VII Padua in Iran: A Study on 150 Patients With Factor VII Deficiency

    by Seyed Mehrab Safdari, Mahmood Barati, Soudabeh Hosseini, Ebrahim Kalantar, Farhad Zaker, Akbar Dorgalaleh

    Introduction: Factor (F) VII Padua is an ultra‐rare type II FVII deficiency characterized by discrepancies in FVII activity across different thromboplastin types. Due to the high prevalence of consanguineous marriages in Iran, rare bleeding disorders, including FVII deficiency, are more common. Accurate identification of FVII Padua is critical to avoid inappropriate treatments and thrombotic risks. Aim: This study aimed to determine the incidence and clinical and laboratory characteristics of FVII Padua among Iranian patients with FVII deficiency. Method: One hundred fifty Iranian patients aged 18 years or older with confirmed FVII deficiency were included. PT testing was performed using rabbit brain, human placenta and recombinant human thromboplastins. Patients with PT discrepancies consistent with FVII Padua underwent genetic analysis of F7 exon 9 for the Arg364Gln mutation. Results: Thirteen patients (8.6%) exhibited PT patterns indicative of FVII Padua. HRM analysis identified nine heterozygous and two homozygous cases for the Padua variant; subsequently, sequencing analysis confirmed the Arg364Gln variant in two patients. Sequencing also revealed four additional variants in exon 9. The confirmed Padua cases presented diverse manifestations, ranging from asymptomatic to symptomatic, including bruising, epistaxis, gastrointestinal bleeding and gum bleeding. Conclusion: FVII Padua is relatively prevalent among Iranian patients with FVII deficiency . Molecular testing is essential for accurate diagnosis, enabling appropriate management and preventing unnecessary interventions. Tailored diagnostic strategies are crucial in regions with high consanguinity rates to optimize patient care and reduce thrombotic risks.

  • International Council for Standardization in Haematology (ICSH) Guidance on the Validation of Laboratory Developed Tests in Haemostasis

    by Chris Gardiner, Akbar Dorgalaleh, Marión Echenagucia, Robert C. Gosselin, Teruto Hashiguchi, Mingting Peng, Alan Neal, Steve Kitchen

    Laboratory developed tests (LDTs) are widely used in clinical hemostasis laboratories. An LDT may be defined as an in vitro diagnostic (IVD) test that is designed, manufactured, and used within a single laboratory. As with all other clinical laboratory tests, LDTs must be validated to ensure fitness for purpose. This may include the assessment of accuracy/comparability, precision, analytical sensitivity, and specificity, reportable range, reference intervals, linearity, and carryover. Not all validation elements will be applicable to all situations, and this will be dictated by the type of assay, the intended use, and the laboratory setting, for example a minor modification of an assay with regulatory approval will require fewer validation procedures than a wholly new test using reagents developed within the laboratory. Many LDTs in the hemostasis laboratory cannot be assessed in the usual fashion, so alternative approaches must be developed.


  • Precision Medicine in Rare Bleeding Disorders

    by Akbar Dorgalaleh, Maha Othman

    Rare bleeding disorders (RBDs) are also referred to by other names, including recessively inherited bleeding disorders, rare coagulation factor deficiencies, and rare congenital bleeding disorders.[1] Traditionally, these disorders include all coagulation factor deficiencies with bleeding tendency, except for hemophilia A and hemophilia B.[1] The estimated incidence of these disorders ranges widely, from 1 per 2 million for factor XIII (FXIII) and prothrombin (FII) deficiency to 1 per 500,000 for FVII deficiency in the general population.[1] [2] Over the last two decades, with rapid progress in laboratory diagnosis, molecular studies, and clinical characterization of bleeding disorders, there have been significant improvements in both case identification and treatment modalities. Additionally, other less common bleeding disorders, characterized by both bleeding tendency and rare incidence, have been included in this category.[1] Today, inherited platelet function disorders, disorders of the fibrinolytic system, and other rare hemorrhagic disorders such as rare forms of von Willebrand disease (VWD) and platelet-type VWD (PT-VWD) can be included in this category. A large number of studies have been conducted on these rare disorders, and a wide range of disease variants have been identified in the underlying genes, illuminating their molecular basis.[3] This progress has advanced significantly from the discovery of the underlying genes for each disorder to the in vitro application of advanced gene editing systems like CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated).[4] Growth has also occurred in therapeutic options, which have evolved from traditional choices such as whole blood transfusion, platelet concentrate, fresh frozen plasma (FFP), and cryoprecipitate to more advanced options: plasma-derived and recombinant or nanoengineered products that are now available for a considerable number of RBDs.[1] Despite all the advances, the shift in therapeutic intervention from traditional general recommendations to more specific personalized therapeutic recommendations (precision medicine) represents a significant improvement that can enhance the quality of life for these patients, as increasingly observed in hemophilia A and B.[5] The advent of next-generation sequencing (NGS) and genome-wide association studies (GWAS), along with the rapid growth of artificial intelligence (AI), may have a significant impact on this field. The identification of genetic modifiers that can directly affect disease phenotype can further accelerate this progress. Due to the importance of this field and its potential impact, this issue of Seminars in Thrombosis and Hemostasis (STH) aims to cover various aspects of RBDs, including laboratory, clinical, and molecular findings, which can potentially influence personalized patient management. With regard to this, in the first paper of this issue, Cassini et al review the clinical, laboratory, and molecular aspects of congenital fibrinogen disorders (CFDs).[6] The authors report that patients with the same fibrinogen variant may have completely different clinical phenotypes. Additionally, they note some established genotype-phenotype correlations in CFDs, such as thrombotic-related dysfibrinogenemia and fibrinogen storage disease, while suggesting that other potential genetic modifiers may be identified through NGS.[6] Due to the important role of genetics, Franchini and Focosi report that among different types of F5 gene mutations, splice site mutations and those associated with premature codon terminations are associated with severe FV deficiency, while the Met2120Thr polymorphism and the HR2 haplotype are associated with a milder phenotype.[7] There is a poor correlation between FV activity levels and severity of clinical presentations. The optimal treatment of the disorder depends on the clinical severity, with antifibrinolytics for management of mild FV deficiency and replacement therapy with FFP for severe deficiency to increase the FV levels to 20 to 25%.[7] Although concomitant reduction of FV and FVIII would be expected to cause a more severe phenotype than separate single deficiencies of each coagulation factor, this is not the case, as patients with combined FV and FVIII deficiency (CF5F8D) experience a milder phenotype, as pointed out by Yakovleva and Zhang in their review.[8] There is a strong correlation between residual levels of FV and FVIII and the severity of clinical presentations in CF5F8D. However, although patients with MCFD2 mutations have lower plasma FV and FVIII activities, factor activity in CF5F8D cannot be used as a predictor of genotype. The mainstay of treatment in CF5F8D is on-demand therapy, and treatment is based on the severity of clinical presentations. When the FV level is above 10% in CF5F8D, bleeding rarely occurs due to FV deficiency, and FV replacement therapy is usually not required at this threshold. According to this review, the main challenge is to determine if and to what extent FV contributes to bleeding in CF5F8D.[8] In the next review, Bernardi and Mariani outline the clinical, laboratory, and molecular aspects of FVII deficiency, one of the most common RBDs.[9] This review highlights that FVII deficiency is one of the most severe RBDs, with a clinical picture that may be even more severe than hemophilia A and B due to a high rate of intracranial hemorrhage (ICH), reported to be around 12% in one study. Despite several discrepancies, there is a modest correlation between FVII activity and severity of clinical presentations, though the same gene variant may be accompanied by heterogeneous clinical manifestations. Patients with FVII activity levels higher than 26% rarely experience spontaneous bleeding episodes. More than 1,000 patients diagnosed with FVII deficiency have been reported, and identified variants can be used for genetic counseling and diagnosis, including prenatal...


  • Correlation between Phenotype and Coagulation Factor Activity Level in Rare Bleeding Disorders: A Systematic Review

    by Behnaz Tavasoli, Alireza Zangooie, Seyed Mehrab Safdari, Taraneh Hoseinnezhad, Ashkan Shabannezhad, Amirreza Alikhani, Zahra Salehi, Akbar Dorgalaleh

    Rare bleeding disorders (RBDs) represent 3 to 5% of congenital bleeding disorders and are primarily inherited in an autosomal recessive manner, with increased prevalence in consanguineous populations. Clinically, RBDs can be accompanied by mild to severe bleeding episodes, often assessed using bleeding assessment tools (BATs) such as the International Society on Thrombosis and Hemostasis (ISTH)-BAT. However, the correlation between bleeding severity and coagulation factor activity levels remains inconsistent. This systematic review investigates this relationship to enhance understanding and improve management strategies for patients with RBD. This review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with the International Prospective Register for Systematic Reviews (PROSPERO) (CRD42024504537). Using the PICO (Population, Intervention, Comparator, and Outcomes) framework, the study focused on RBD patients to explore the correlation between coagulation factor activity levels and bleeding severity. A comprehensive search was conducted across PubMed, Scopus, and Web of Science until April 1, 2024, with data extracted on bleeding severity, phenotype, and coagulation factor activity levels. The analysis highlights complex and often inconsistent relationships between coagulation factor levels and the severity of bleeding. In cases of fibrinogen deficiency, three out of four studies (n = 73 of 111 cases, 66%) demonstrated a moderate to strong correlation between fibrinogen levels and bleeding severity. In prothrombin deficiency, one of two studies (n = 16 of 29 cases, 55%) found a strong correlation between FII levels and bleeding severity. Four of six studies (n = 106 of 139 cases, 76%) in FV deficiency found a weak or no correlation between factor activity and bleeding severity. In combined FV and FVIII deficiency, two of three studies (n = 26 of 60 cases, 43%) found a significant correlation between factor activity and bleeding severity. In FVII deficiency, four (of nine) studies with a study population of 325 patients (65%) found a weak correlation between factor activity and severity of bleeding. Almost all studies (five of six studies, n = 114 of 118 patients, 97%) in FX deficiency revealed a strong correlation between FX levels and bleeding severity. In FXI deficiency, most studies (five of seven studies, n = 254 patients, 93%) found a weak or no correlation between factor activity and bleeding severity or symptoms. For FXIII deficiency, there was a moderate to strong correlation between FXIII activity and bleeding severity in all three studies (n = 61 patients). In conclusion, despite current controversies, this review highlights a moderate or strong correlation between factor activity and bleeding severity in fibrinogen, FX, and FXIII deficiencies, but no correlation or weak correlation for FV, FVII, and FXI deficiencies. Further prospective studies with standardized BATs on a large number of patients are needed to better understand these relationships and optimize patient management. * These authors contributed equally to this article. Article published online: 05 December 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA


  • Factor XIII Deficiency: Laboratory, Molecular, and Clinical Aspects

    by Akbar Dorgalaleh, Sina Jozdani, Masoumeh Kiani Zadeh

    Factor XIII-A (FXIII-A) deficiency is an ultra-rare bleeding disorder characterized by high rates of morbidity and mortality, primarily resulting from intracranial hemorrhage, umbilical cord bleeding, and miscarriage, whereas patients with severe FXIII-B deficiency present with a milder phenotype. Although the estimated incidence of severe FXIII-A deficiency is one per 2 million, a high prevalence ranging from 0.8 to 3.5% has been observed for heterozygous FXIII-A deficiency. Unlike most bleeding disorders, individuals with heterozygous FXIII-A deficiency, particularly women, are more likely to experience hemorrhagic complications during hemostatic challenges. About 200 Mutations have been observed in F13A and F13B genes, with most being missense mutations, while large deletions are the rarest. There is no correlation between genotype and phenotype and a moderate to strong correlation between factor activity and clinical severity in FXIII-A deficiency, making it difficult to predict bleeding patterns based on genotype and FXIII activity levels. Primary prophylaxis is mandatory for all patients with severe FXIII-A deficiency, while those with heterozygous deficiency are generally asymptomatic and may require on-demand therapy during hemostatic challenges, most commonly in women. On the other hand, patients with severe FXIII-B deficiency may only require on-demand therapy, while heterozygotes are generally asymptomatic. Although there are general recommended therapeutic regimens for prophylaxis or on-demand therapy in different situations, personalized pharmacokinetic-based replacement therapy represents the optimal approach that can optimize intervention efficacy. In such an approach, several factors may affect the effectiveness of treatment and determine the dose and type of intervention, including the classification of FXIII deficiency, residual plasma levels of FXIII, clinical situation requiring intervention, age, weight, and also gender.


  • The History of Rare Bleeding Disorders

    by Akbar Dorgalaleh, Behnaz Tavasoli, Saeed Hassani, Narjes Ramezanzadeh, Kimia Fathalizade, Farzaneh Hashemi, Zahra Feily, Melika Khademi, Zhino Kohzadi, Roghayeh Gholizadeh Doran Mahalleh, et al.

    Deficiencies in coagulation factors I (FI), FII, FV, combined FV and FVIII (CF5F8) and vitamin K-dependent coagulation factors FVII, FX, FXI, and FXIII have been referred to as rare bleeding disorders (RBDs), rare coagulation factor deficiencies (RCFDs), or recessively inherited coagulation disorders. Fibrinogen was most likely the first member of this group to be identified, with reports of its discovery spanning from 1859 to 1966. If not, then the first coagulation factor to be identified was prothrombin in 1894, and the last coagulation factor to be found was FX in 1956, about 60 years later. The first patient to be diagnosed with an RBD was a 9-year-old boy with afibrinogenemia in 1920 and the vitamin K-dependent coagulation factors deficiency was the most recent RBD in this group to be identified in a 3-month-old child in 1966. The initial therapeutic option for nearly all patients with RBDs was whole blood transfusion; this was replaced in 1941 by fresh frozen plasma (FFP), and then in later years by cryoprecipitate and coagulation factor concentrates. Fibrinogen concentrate was the first coagulation factor concentrate produced in 1956. Coagulation factor concentrate is now available for FI, FVII, FX, FXI, and FXIII; however, FFP and/or platelet transfusion are the only treatments available for FV deficiency. The only recombinant concentrates available for RBDs are for FVII and FXIII, which date from 1988 and the 2000s, respectively. Even though the clinical presentations, diagnosis, and management of lesser-known bleeding disorders have improved significantly in recent decades, more studies are needed to reveal the hidden aspects of these disorders in order to overcome diagnostic and therapeutic challenges and ultimately improve the quality of life for those who are affected.


  • Cancer-associated thrombosis: the role of inherited thrombophilia

    by Anita Zia, Mahmood Shams, Ali Dabbagh, Milad Shahsavari, Akbar Dorgalaleh

    Cancer-associated thrombosis (CAT) is a common complication and a major cause of morbidity and mortality in patients with active cancers. CAT is common in various malignancies, particularly pancreatic, ovarian, gastric, colorectal, and hematologic cancers. In fact, CAT is a complicated multifactorial complication that may be influenced by the type of cancer as well as by the genetic background and inheritance of thrombophilic variants and elevated concentrations of coagulation factors. Several studies have shown the prominent role of inherited thrombophilias, such as prothrombin 20210, factor V Leiden, factor XIII Val34Leu, MTHFR C677T, in the occurrence of CAT, while others have found no correlation between them and CAT. In the present review, we have attempted to investigate the possible role of inherited thrombophilia in the occurrence of CAT.